| BSX |
Report |
Q2 2026 organic net sales growth |
BEAT |
pred ~5.5% vs. cons 5.3% |
MEDIUM |
| BSX |
Report |
Q2 2026 adjusted EPS |
BEAT |
pred ~$0.84 vs. cons $0.83 |
MEDIUM |
| BSX |
Report |
Q2 2026 reported revenue |
IN-LINE |
pred ~$5.40B vs. cons $5.39B |
HIGH |
| BSX |
Guide |
Organic net sales growth |
LOWER |
guide ~7.0% midpoint vs. cons 7.1% (FY2026) |
MEDIUM |
| BSX |
Guide |
Adjusted EPS |
BETTER |
guide ~$3.38 midpoint vs. cons $3.35 (FY2026) |
MEDIUM |
| BSX |
Guide |
Organic net sales growth |
LOWER |
guide ~6.25% midpoint vs. cons 6.6% (Q3 2026) |
MEDIUM |
| BSX |
Guide |
Adjusted EPS |
UNCHANGED |
guide ~$0.84 midpoint vs. cons $0.84 (Q3 2026) |
MEDIUM |
| BSX |
Guide |
WATCHMAN sequential revenue growth commentary |
LOWER |
guide ~0% vs. cons 2% (Q3 2026) |
MEDIUM |
| BSX |
Return |
Day-1 residual (stock − beta × S&P 500) |
+8.0% |
— |
MEDIUM |
| BSX |
Return |
5-day cumulative residual |
+5.0% (FADE) |
A low-bar Q2 beat and preservation of FY2026 EPS should trigger a relief rally, but Q3 organic growth below consensus and another quarter of roughly flat sequential WATCHMAN revenue would pull out-period revenue estimates lower and partially reverse the day-1 move. |
MEDIUM |